Phase 2
Completed N=15
Calcium Channel Blockade in Primary Aldosteronism
Primary aldosteronism · Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Source: ClinicalTrials.gov NCT04179019 ↗
Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcomePrimary: Change in 24-hour Urinary Aldosterone Excretion Rate — 0.21 mcg/24h — p=0.96
Summary
This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in 24-hour Urinary Aldosterone Excretion Rate |
0.21 | 0.96 |
| PRIMARY Change in Plasma Aldosterone Concentration |
9.81 | 0.29 |
| SECONDARY Acute Change in Plasma Aldosterone Concentration |
-0.86 | 0.83 |
Eligibility Criteria
Inclusion Criteria
- Confirmed diagnosis of primary aldosteronism
- Idiopathic bilateral hyperaldosteronism subtype based on adrenal venous sampling
- Primary aldosteronism treated with medical therapy (not surgery)
- Plasma renin activity 1.0 ng/mL/h
- Anemia
- leukopenia
- thrombocytopenia
- pregnant
- breastfeeding
Data sourced from ClinicalTrials.gov (NCT04179019). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.